Pharmaceuticals
enterpriseTarget: Drug Developer
If you are a drug developer dealing with high failure rates in CVD trials — this project developed a proof-of-concept therapy that targets specific pathogenic B cells to reduce disease progression.
B-specific · Project
B-cell Biomarkers for Predicting and Treating Heart Disease and Stroke
healthPrototypeTRL 3
Think of your immune system as a security team; some specific 'guards' called B-cells might actually be making heart disease worse. This project identifies these specific guards to predict who is at risk of a heart attack or stroke. Once identified, the team is working on a way to remove only the harmful guards to prevent the disease.
By the numbers
1
proof-of-concept therapy to eliminate pathogenic B cells
6
consortium partners
40-105
age range of adults in population-based cohorts
The business problem
What needed solving
Current cardiology lacks precise biomarkers to identify which patients are at high risk of plaque rupture leading to stroke or heart attack. This leads to generic treatments rather than tailored prevention.
The solution
What was built
The project is developing B-cell genetic and protein markers and at least 1 proof-of-concept therapy to remove harmful B cells.
Audience
Who needs this
Biopharmaceutical companiesPrecision medicine diagnostic firmsCardiovascular research institutesSpecialized cardiology clinics
Business applications
Who can put this to work
Diagnostics
mid-sizeTarget: Medical Testing Lab
If you are a testing lab dealing with a lack of precise risk markers for stroke — this project developed B-cell genetic and protein markers that allow for better patient stratification.
Healthcare Providers
anyTarget: Cardiology Clinic
If you are a clinic dealing with generic treatment plans for atherosclerosis — this project developed a means of patient stratification to provide tailored preventive interventions.
Frequently asked
Quick answers
What is the cost or price of the resulting therapy?
Based on available project data, no pricing or cost information has been disclosed as the project is in the research and proof-of-concept stage.
Can this be produced at an industrial scale?
The project is currently focused on developing a proof-of-concept therapy; industrial scaling details are not mentioned in the current reports.
What are the IP and licensing options?
Based on available project data, the project implements an open science platform, but specific patent or licensing terms for the therapy are not listed.
What is the timeline for clinical availability?
The project runs from 2023-10-01 to 2027-09-30, suggesting that results and proof-of-concept therapies will be finalized by late 2027.
How will this integrate into existing cardiology practice?
The project aims to impact practice through a targeted dissemination approach to healthcare professionals and new means of patient stratification.
Consortium
Who built it
The consortium is heavily academic, consisting of 4 universities and 1 research institution, with a low industry ratio of 17% (1 SME). This suggests the project is primarily driven by discovery and validation rather than immediate commercial manufacturing, though the inclusion of an SME provides a bridge to market application.
How to reach the team
Contact Universiteit Leiden regarding B-cell markers for CVD
Next steps
Talk to the team behind this work.
Contact us to identify potential licensing opportunities for B-cell therapeutic targets.
More in Health & Biomedical
See all Health & Biomedical projects →